NCT00002413已完成2 期
An Open Label Study of MKC-442 in at Least Triple Drug Combination in Patients Previously Treated With Nucleoside Reverse Transcriptase and Protease Inhibitors and Who Are Naive to Non-Nucleoside Reverse Transcriptase Inhibitors
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
研究概览
简要总结
The purpose of this study is to see if it is safe and effective to give MKC-442 plus at least two other anti-HIV drugs to patients who have never been treated with nonnucleoside reverse transcriptase inhibitors but who have been treated with nucleoside reverse transcriptase inhibitors and protease inhibitors. This study also determines how long a drug combination including MKC-442 is effective.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Based on medical history, medical condition, prior use of antiretroviral drugs, and genotypic analysis of the predominant strain of HIV-1 isolated from plasma, administration of at least 2 available antiviral agents by prescription may be given with MKC-
- •Patients must have:
- •- HIV infection with HIV-1 RNA greater than or equal to 2,000 by Roche Amplicor method, within 30 days of entry.
- •Prior Medication:
- •Prior nucleoside reverse transcriptase and protease inhibitors.
- •Cytotoxic chemotherapy more than 30 days prior to entry.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Malabsorption or severe chronic diarrhea within 30 days prior to entry, or inability to consume adequate oral intake because of chronic nausea, emesis, or abdominal or esophageal discomfort.
- •Inadequately controlled seizure disorder.
- •Acute and clinically significant medical event within 30 days of screening.
- •Any clinical or laboratory abnormality greater than Grade 3 toxicity, with the exception of the listed laboratory values.
- •Prior Medication:
- •Non-nucleoside reverse transcriptase inhibitor therapy.
- •Any unapproved experimental antiretroviral therapy.
- •Prior Treatment:
- •Radiation therapy within 30 days of entry, except to a local lesion.
- •Transfusion of blood or blood products within 21 days of screening.
- •Risk Behavior:
- •Active substance abuse that may interfere with compliance or protocol evaluations.
研究者
相似试验
终止
2 期
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsHIV InfectionsNCT00002420Bristol-Myers Squibb25
已完成
2 期
A Study of MKC-442 in Combination With Other Anti-HIV DrugsHIV InfectionsNCT00002412Triangle Pharmaceuticals
已完成
2 期
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleCystic FibrosisNCT04126473Eloxx Pharmaceuticals, Inc.17
已完成
2 期
A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNCT05185622Santhera Pharmaceuticals54
已完成
2 期
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic DuodenitisEosinophilic GastritisEosinophilic GastroenteritisEosinophilic DuodenitisNCT03664960Allakos Inc.58